Dr. Sznol on Immunotherapy in Patients With RCC

Mario Sznol, MD, professor of Medicine, Yale Cancer Center, shares how to discuss immunotherapy as a treatment option for patients with renal cell carcinoma (RCC).

When talking to patients regarding their treatment plan, Sznol emphasizes the benefits of immunotherapy, such as durable remissions and a favorable toxicity profile.

Sznol stresses that even if patients do not respond to immunotherapy in the first-line setting, there are still other available therapies that can be used in later lines of therapy.

<<<

View more from 2016 New York GU